Drug lookup | Fillwise

DABIGATRAN ETEXILATE

4 general benefit · 2 not a benefit

Other products in the same Health Canada class (B01A) — coverage varies; not interchangeable

Apixaban (Eliquis): general benefit
Edoxaban (Lixiana): general benefit
Enoxaparin (Noromby): general benefit
Rivaroxaban (Xarelto): general benefit
Warfarin (Coumadin): general benefit, Not a benefit
Dalteparin (Fragmin): limited Use 186, 187, 188, 189

5 more in the class list below

Apo-Dabigatran · DIN 02468905 · 110mg · capsule

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Apo-Dabigatran · DIN 02468905 Manufacturer: Apotex Inc.; listing date 2019-05-31 Health Canada: Marketed since 2022-10-05 · brand APO-DABIGATRAN · ATC B01AE07 DABIGATRAN ETEXILATE · form Capsule · route Oral · ingredients DABIGATRAN ETEXILATE (DABIGATRAN ETEXILATE MESILATE) 110 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Dabigatran: Formulary list price $1.2540/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2540 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95755 · Verify on the e-Formulary ↗ (DIN 02468905)

Source record

DIN 02468905: Apo-Dabigatran Raw flags: sec3=Y Item: 201200084; group id 252; item number 0446; lccId None; manufacturer id APX Source form: Cap; strength: 110mg Recorded listing: General benefit Source prices (unrounded): $1.2540; ministry $1.2540 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02468905 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95755

Interchangeable products

Pradaxa · DIN 02312441 · $1.2540

Shortage status: active shortage (reported 2026-08-18, estimated to end 2026-10-23, last updated 2026-08-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02468905

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pradaxa · DIN 02312441 · 110mg · capsule

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Pradaxa · DIN 02312441 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2012-04-24 Health Canada: Marketed since 2008-07-03 · brand PRADAXA · ATC B01AE07 DABIGATRAN ETEXILATE · form Capsule · route Oral · ingredients DABIGATRAN ETEXILATE (DABIGATRAN ETEXILATE MESILATE) 110 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $1.2540 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79795 · Verify on the e-Formulary ↗ (DIN 02312441)

Source record

DIN 02312441: Pradaxa Raw flags: sec3=Y Item: 201200084; group id 252; item number 0446; lccId None; manufacturer id BOE Source form: Cap; strength: 110mg Recorded listing: General benefit Source prices (unrounded): $1.8060; ministry $1.2540 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02312441 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79795

Interchangeable products

Apo-Dabigatran · DIN 02468905 · $1.2540

Shortage status: resolved shortage (ended 2020-02-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02312441

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Dabigatran · DIN 02468913 · 150mg · capsule

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Apo-Dabigatran · DIN 02468913 Manufacturer: Apotex Inc.; listing date 2019-05-31 Health Canada: Marketed since 2019-02-04 · brand APO-DABIGATRAN · ATC B01AE07 DABIGATRAN ETEXILATE · form Capsule · route Oral · ingredients DABIGATRAN ETEXILATE (DABIGATRAN ETEXILATE MESILATE) 150 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Dabigatran: Formulary list price $1.2540/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2540 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 02468913: Apo-Dabigatran Raw flags: sec3=Y Item: 201200085; group id 252; item number 0447; lccId None; manufacturer id APX Source form: Cap; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $1.2540; ministry $1.2540 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02468913 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95756

Interchangeable products

Pradaxa · DIN 02358808 · $1.2540

Shortage status: anticipated shortage (last updated 2026-09-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02468913

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pradaxa · DIN 02358808 · 150mg · capsule

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Pradaxa · DIN 02358808 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2012-04-24 Health Canada: Marketed since 2013-03-28 · brand PRADAXA · ATC B01AE07 DABIGATRAN ETEXILATE · form Capsule · route Oral · ingredients DABIGATRAN ETEXILATE (DABIGATRAN ETEXILATE MESILATE) 150 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $1.2540 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84384 · Verify on the e-Formulary ↗ (DIN 02358808)

Source record

DIN 02358808: Pradaxa Raw flags: sec3=Y Item: 201200085; group id 252; item number 0447; lccId None; manufacturer id BOE Source form: Cap; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $1.8060; ministry $1.2540 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02358808 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84384

Interchangeable products

Apo-Dabigatran · DIN 02468913 · $1.2540

Shortage status: resolved shortage (ended 2022-02-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02358808

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Dabigatran · DIN 02468891 · 75mg · capsule

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Apo-Dabigatran · DIN 02468891 Manufacturer: Apotex Inc.; listing date 2019-10-31 Health Canada: Marketed since 2019-08-14 · brand APO-DABIGATRAN · ATC B01AE07 DABIGATRAN ETEXILATE · form Capsule · route Oral · ingredients DABIGATRAN ETEXILATE (DABIGATRAN ETEXILATE MESILATE) 75 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Source record

DIN 02468891: Apo-Dabigatran Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 201200098; group id 252; item number 0445; lccId None; manufacturer id APX Source form: Cap; strength: 75mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.6443; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02468891 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95754

Interchangeable products

Pradaxa · DIN 02312433 · not recorded

Shortage status: resolved shortage (ended 2024-07-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02468891

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pradaxa · DIN 02312433 · 75mg · capsule

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2025-12-02 — choose a marketed DIN from the same-category list.Discontinued 2025-12-02 · checked 2026-09-02

StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2025-12-02 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2025-12-02 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Pradaxa · DIN 02312433 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2019-10-31 Health Canada: Cancelled post market since 2025-12-02 · brand PRADAXA · ATC B01AE07 DABIGATRAN ETEXILATE · form Capsule · route Oral · ingredients DABIGATRAN ETEXILATE (DABIGATRAN ETEXILATE MESILATE) 75 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription

Check this DIN again · Health Canada product record

Pradaxa: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79794 · Verify on the e-Formulary ↗ (DIN 02312433)

Source record

DIN 02312433: Pradaxa Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 201200098; group id 252; item number 0445; lccId None; manufacturer id BOE Source form: Cap; strength: 75mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02312433 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79794

Interchangeable products

Apo-Dabigatran · DIN 02468891 · not recorded

Shortage status: discontinued (2025-10-24, reported by BOEHRINGER INGELHEIM (CANADA) LTD LTEE); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02312433

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2025-12-02 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (20:12 Coagulants and Anti-Coagulants) and how they are covered

Matched class: 20:12 Coagulants and Anti-Coagulants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: APIXABAN, ENOXAPARIN, RIVAROXABAN Some products covered without a code (check the product listing): EDOXABAN, WARFARIN 20:12 Coagulants and Anti-Coagulants

APIXABAN

· 38 products · General benefit · strengths: 2.5mg, 5mg · Tab

ENOXAPARIN

· 37 products · General benefit · strengths: 20mg/0.2mL, 30mg/0.3mL, 40mg/0.4mL, 60mg/0.6mL, 80mg/0.8mL, 120mg/0.8mL, 100mg/mL, 150mg/mL, 300mg/3mL · Inj Sol-0.2mL Pref Syr (Preservative-Free), Inj Sol-0.3mL Pref Syr (Preservative-Free), Inj Sol-0.4mL Pref Syr (Preservative-Free), Inj Sol-0.6mL Pref Syr (Preservative-Free), Inj Sol-0.8mL Pref Syr (Preservative-Free), Inj Sol-1mL Pref Syr (Preservative-Free), Inj Sol-3mL Vial Pk (With Preservative)

RIVAROXABAN

· 48 products · General benefit · strengths: 2.5mg, 10mg, 15mg, 20mg · Tab

WARFARIN

· 23 products · Listed, not a benefit (8), General benefit (14), Off-Formulary Interchangeable, not an ODB benefit (1) · strengths: 1mg, 2mg, 2.5mg, 3mg, 4mg, 5mg, 6mg, 10mg · Tab

DALTEPARIN SODIUM

· 10 products · Limited Use, codes 186, 187, 188, 189 · strengths: 3500IU/0.28mL, 7500IU/0.3mL, 2500IU/0.2mL, 5000IU/0.2mL, 10000IU/0.4mL, 12500IU/0.5mL, 15000IU/0.6mL, 18000IU/0.72mL, 16500IU/0.66mL, 25000IU/mL · Inj Pref Syr, Inj Pref Syr-0.66mL Pk, Multidose 3.8mL Pk

FONDAPARINUX SODIUM

· 4 products · Limited Use, codes 378 (2), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 2.5mg/0.5mL, 7.5mg/0.6mL · Inj Sol-Pref Syr 0.5mL Pk (Preservative Free), Inj Sol-Pref Syr 0.6mL Pk (Preservative Free)

NADROPARIN CALCIUM

· 7 products · Limited Use, codes 186, 187, 188, 189 · strengths: 9500IU/mL, 19000IU/mL · Pref Syr-0.3mL Pk, Pref Syr-0.4mL Pk, Pref Syr-0.6mL Pk, Pref Syr-0.8mL Pk, Pref Syr-1.0mL Pk

TICAGRELOR

· 10 products · Off-Formulary Interchangeable, not an ODB benefit (5), Limited Use, codes 441 (5) · strengths: 60mg, 90mg · Tab

TINZAPARIN SODIUM

· 11 products · Limited Use, codes 186, 187, 188, 189, 323 · strengths: 2500IU/0.25mL, 8000IU/0.4mL, 12000IU/0.6mL, 16000IU/0.8mL, 3500IU/0.35mL, 4500IU/0.45mL, 10000IU/0.5mL, 14000IU/0.7mL, 18000IU/0.9mL, 10000IU/mL, 20000IU/mL · Inj Pref Syr, Inj-2mL Pk

EPTIFIBATIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.75mg/mL, 2mg/mL · 100mL Vial Pk, 10mL Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 20:12 20:12:04 Direct Factor Xa Inhibitors

EDOXABAN

· 11 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3), General benefit (8) · strengths: 15mg, 30mg, 60mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 20:12:04 20:12:16 Hemostatics

TRANEXAMIC ACID

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 20:12:16

Full class listing Related classes: 20:04 Antianemia Drugs, 20:16 Hematopoietic Agents, 20:24 Hemorrheologic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.

Other drugs whose Health Canada label lists a similar indication: atrial fibrillation

From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: DIGOXIN DIGOXIN · General benefit • Atrial Fibrillation: pms-DIGOXIN is indicated for the control of ventricular response rate in patients with chronic atrial fibrillation. 1.1 Pediatrics Pediatrics (under 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of pms-DIGOXIN in pediatric patients has been established. PM: https://pdf.hres.ca/dpd_pm/00069390.PDF; date NOV 23, 2022; DIN 02242320; fetched 2026-09-10 Product monograph • Atrial Fibrillation: pms-DIGOXIN is indicated for the control of ventricular response rate in patients with chronic atrial fibrillation. PM: https://pdf.hres.ca/dpd_pm/00069390.PDF; date NOV 23, 2022; DIN 02242320; fetched 2026-09-10 Product monograph EDOXABAN · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3), General benefit (8) 1 INDICATIONS Sandoz Edoxaban (edoxaban tablets) is indicated for: • Prevention of stroke and systemic embolic events in patients with atrial fibrillation, in whom anticoagulation is appropriate. PM: https://pdf.hres.ca/dpd_pm/00080468.PDF; date MAY 05, 2025; DIN 02553414; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26

What the Health Canada label says it is for

INDICATIONS AND CLINICAL USE PRADAXA (dabigatran etexilate) is indicated for the: • prevention of venous thromboembolic events (VTE) in patients who have undergone elective total hip replacement (THR) or total knee replacement (TKR) surgery • treatment of venous thromboembolism events (deep vein thrombosis [DVT], pulmonary embolism [PE]) and prevention of recurrent DVT and PE • prevention of stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation is appropriate Geriatrics (>65 years of age): Most older subjects demonstrate an increase in exposure to dabigatran, usually in association with age-related decline of renal function (see WARNINGS AND PRECAUTIONS, Renal, and DOSAGE AND ADMINISTRATION, Renal Impairment). Pediatrics (<18 years of age): The safety and efficacy of PRADAXA have not been established in children <18 years of age. Therefore, PRADAXA is not indicated in this patient population. https://pdf.hres.ca/dpd_pm/00080323.PDF PM date: APR 22, 2025 Source product: PRADAXA; DIN 02312441; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Dabigatran · DIN 02468905 Shortage status: active shortage (reported 2026-08-18, estimated to end 2026-10-23, last updated 2026-08-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02468905

Check this DIN again

Pradaxa · DIN 02312433 Shortage status: discontinued (2025-10-24, reported by BOEHRINGER INGELHEIM (CANADA) LTD LTEE); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02312433

Check this DIN again

Other review policies

For Apo-Dabigatran, Pradaxa: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026